Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab Combined With AVD in First-line Advanced Classical Hodgkin's Lymphoma
NCT04067037Phase 2Active, not recruiting
- Sponsor
- Henan Cancer Hospital
- Start
- Aug 2019
- Primary completion
- Jan 2026
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of camrelizumab in classical Hodgkin lymphoma (cHL), sponsored by Henan Cancer Hospital. Primary endpoint: Complete Metabolic Response Rate. Started Aug 2019; status: active, not recruiting.
02
Drugs
camrelizumab
03
Conditions
classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on NCT04067037.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04067037.